Anti-ctla4 antibodies and methods of use thereof
AssigneeXilio Development, Inc.
InventorMargaret Karow
Life of this patent
Estimating the term…
Abstract
The invention provides anti-CTLA4 binding proteins (e.g., antibodies, bispecifc antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the anti-CTLA4 binding proteins.
Claims21
1-54. (canceled)
A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an anti-CTLA4 antibody, wherein the anti-CTLA4 antibody comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein
- the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- and the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 24, and
- wherein the antibody comprises a heavy chain constant region (CH) comprising substitutions S239D and I332E, wherein the amino acid residues are numbered according to EU index as in Kabat.
A method of inhibiting tumor growth in a subject comprising administering to the subject an effective amount of an anti-CTLA4 antibody, wherein the anti-CTLA4 antibody comprises a light chain variable (VL) region and a heavy chain variable (VH) domain, wherein
- the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- and the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 24, and
- wherein the antibody comprises a heavy chain constant region (CH) comprising substitutions S239D and I332E, wherein the amino acid residues are numbered according to EU index as in Kabat.
A method of increasing cellular cytotoxicity against cancer cells in a subject comprising administering to the subject an effective amount of an anti-CTLA4 antibody, wherein the anti-CTLA4 antibody comprises a light chain variable (VL) region and a heavy chain variable (VH) domain, wherein
- the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- and the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 24, and
- wherein the antibody comprises a heavy chain constant region (CH) comprising substitutions S239D and I332E, wherein the amino acid residues are numbered according to EU index as in Kabat.
Dependencies are inferred from the claim text.